SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”), have until May 4, 2026 to seek appointment as lead plaintiff of the Boston Scientific class action lawsuit. Captioned Troike v. Boston Scientific Corporation, No. 26-cv-40075 (D. Mass.), the Boston Scientific class action lawsuit charges Boston ...

BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Executives Misrepresented U.S. Electrophysiology Volumes: Levi & Korsinsky Accessibility StatementSkip NavigationAlert: Claims Focus on Alleged Misrepresentations About U.S. Electrophysiology Procedure GrowthNEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Boston Scientific Corporation (NYSE: BSX) securities of a pending securit ...

Boston Scientific Corporation ( BSX ), which has been around for four and a half decades and is one of the preeminent institutions in the medical devices terrain, hasn’t done a great deal of goodAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha ...

Boston Scientific Corporation ( BSX ), which has been around for four and a half decades and is one of the preeminent institutions in the medical devices terrain, hasn’t done a great deal of goodAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Boston Scientific Corporation (NYSE: BSX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between July 23, 2025, and February 3, 2026. Find out if you qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. Boston Scientific shares fell $16.12 per share, a decline of approximately 17.6%, after the Company disclosed s ...

Robbins LLP Urges BSX Stockholders Who Lost Money Investing in Boston Scientific Corporation to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that deve ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Boston Scientific Corporation common stock between July 23, 2025, and February 3, 2026, of the May 4, 2026, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Boston Scientific common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by May 4, 2026 [3]. - The lawsuit alleges that during the Class Period, Boston Scientific's management made misleading statements about the U.S. Electrophysiology segment's growth, leading to a net income miss and disappointing guidance for the first half of fiscal 2026 [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding its financial outlook and market competition [1][4]. Group 1: Class Action Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation, and it involves purchasers of Boston Scientific common stock from July 23, 2025, to February 3, 2026 [1]. - Investors have until May 4, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Boston Scientific and its executives misrepresented the company's revenue outlook and downplayed risks from market competition [4]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year ago [5]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year [5]. - The adjusted EPS for Q4 2025 was $0.80, compared to $0.70 a year ago, and for the full year, it was $3.06, compared to $2.51 a year ago [5]. - Following the financial results announcement, Boston Scientific's stock price fell more than 17% [5]. Group 3: Company Background - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [7].

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...